Table 2.
Disease characteristics.
| Subgroup | N (%) | |
|---|---|---|
| Tumor specimen | ||
| Tissue | 912 (92.9%) | |
| Cytology | 70 (7.1%) | |
| Histologic subtype | ||
| Adenocarcinoma | 474 (48.3%) | |
| Squamous | 280 (28.5%) | |
| SCLC | 142 (14.5%) | |
| NSCLC NOS | 31 (3.2%) | |
| LCNEC | 17 (1.7%) | |
| Other | 37 (3.8%) | |
| PD-L1 | ||
| <1% | 180 (27.1%) | |
| 1–49% | 247 (37.2%) | |
| ≥50% | 237 (35.7%) | |
| Driver mutations | ||
| No | 368 (71.8%) | |
| Yes | 144 (28.2%) | |
| Stage at treatment initiation | ||
| II | 2 (0.2%) | |
| IIIA | 36 (3.7%) | |
| IIIB | 62 (6.3%) | |
| IIIC | 17 (1.7%) | |
| IVA | 357 (36.4%) | |
| IVB | 508 (51.7%) | |
| Metastatic sites | ||
| Contralateral Lung | 383 (39%) | |
| Pleura | 348 (35.4%) | |
| Brain | 188 (19.1%) | |
| Bone | 310 (31.5%) | |
| Liver | 194 (19.7%) | |
| Adrenal gland | 182 (18.5%) | |
| Other | 309 (31.5%) | |
| Checkpoint inhibitor | ||
| PD-1 inhibitor | 670 (68.1%) | |
| PD-L1 inhibitor | 221 (22.5%) | |
| PD-1 + CTLA-4 inhibitor | 92 (9.4%) | |
| Concurrent chemotherapy | ||
| No | 499 (50.8%) | |
| Platinum-pemetrexed | 211 (21.5%) | |
| Platinum-etoposide | 157 (16%) | |
| Platinum-taxane | 103 (10.5%) | |
| Single-agent chemotherapy | 12 (1.2%) | |
| Concurrent radiotherapy | 193 (19.8%) | |
| Objective Response | ||
| Complete response (CR) | 6 (0.7%) | |
| Partial response (PR) | 200 (22.1%) | |
| Stable disease (SD) | 249 (27.5%) | |
| Progressive disease (PD) | 450 (49.7%) | |
| Subsequent therapy | ||
| Chemotherapy | 345 (89.8%) | |
| Targeted therapy | 17 (4.4%) | |
| Chemoimmunotherapy | 14 (3.7%) | |
| Radiotherapy | 5 (1.3%) | |
| Immunotherapy | 3 (0.8%) |
Abbreviations: LCNEC, large-cell neuroendocrine carcinoma; NSCLC NOS, non-small-cell lung cancer not otherwise specified; SCLC, small-cell lung cancer.